I'm excited about $OSTX as it's just 11% away from its all-time high of $4.60. If it breaks through that level, I believe we could see a strong uptrend without any resistance to hold it back, potentially leading to significant gains in the coming weeks.

I believe OS Therapies is on the verge of a significant breakthrough with their OST-HER2 treatment, especially with the upcoming topline data expected in Q4 2024. The lack of approved treatments for Osteosarcoma makes OSTX a compelling investment opportunity as their trial data could greatly impact the stock price.

OS Therapies ($OSTX) gained serious attention and saw a 5% jump in after-hours trading on Thursday after getting recognition from major investor communities. Hoping this momentum continues on Friday, I believe it’s set for a solid short-term spike given its new exposure.

Given OSTX's proactive advancements in their Phase 2b clinical trials and the significant revenue potential from out-licensing deals, I believe the stock is positioned for substantial growth. Their innovative treatments for solid tumors add a solid future outlook.

With recent media exposure and strong potential in developing innovative cancer treatments, I believe OSTX is positioned for significant growth. Their progress in clinical trials and revenue opportunities make it a solid long-term investment.